Glucosylceramide synthase-IN-1 (T-036) 是一种有效的、可穿过血脑屏障的和具有口服活性的 glucosylceramide synthase (GCS) 抑制剂，对人 GCS 和小鼠 GCS 的 IC50 分别为 31 nM 和 51 nM。Glucosylceramide synthase-IN-1 可用于戈谢病研究。
货号:ajcx38388
CAS:2601393-20-6
分子式:C24H20F4N2O3
分子量：460.42
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Glucosylceramide synthase-IN-1 (T-036) a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research[1].

Glucosylceramide synthase-IN-1 (T-036) potently reduces the GCS product, catalyze glucosylceramide (GlcCer), in the fibroblasts with Gaucher's disease (EC50 of 7.6 nM)[1].

Glucosylceramide synthase-IN-1 (T-036) has good oral exposure (BA = 67%) and moderate brain penetration (Kpuu,brain = 0.11). Administration of a single dose of Glucosylceramide synthase-IN-1 (T-036) reduces GlcCer in the plasma and cerebral cortex of wild-type mice, and administration of Glucosylceramide synthase-IN-1 (T-036) for 2 months significantly reduces glucosylsphingosine (GlcSph) in the cerebral cortex of the Gaucher's disease mouse model[1].

[1]. Yuta Tanaka, et al. Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore. J Med Chem. 2022 Mar 10;65(5):4270-4290